Skip to content Skip to footer
Subscribe Now
Viewpoints_Brian Quigley
VIEWPOINTS

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

Shots: Brian spoke about why Respira Technologies has been rebranded as Qnovia Brian also talked about how Qnovia is working to advance its first inhalable prescription smoking cessation therapy and its applications The interview summarizes how this rebranding will accelerate Qnovia’s technology and products from others in the biotechnology space  Smriti: Would you please start off…
December 12, 2022

Read more

Viewpoints_Dr. Volker Knappertz
VIEWPOINTS

Dr. Volker Knappertz, EVP R&D, Aurinia Shares Insights on LUPKYNIS MAA from EMA

Shots: Volker spoke about the granting of marketing authorization by EC to treat adults with active lupus nephritis.The approval was based on the results of the P-III AURORA study  Volker also talked about the collaboration between Aurinia and Otsuka Pharmaceutical for the development and commercialization of LUPKYNIS The interview gives an understanding of how Aurinia…
December 7, 2022

Read more

Viewpoints_Dr. Robert Kowal
VIEWPOINTS

Dr. Robert Kowal, Vice President at Medtronic Shares Insights on a New Clinical Study on Micra AV Leadless Pacing Performance

Shots: Robert spoke about the publication of the new study in the Heart Rhythm Journal about the Micra AV leadless pacemaker and how it is an effective therapy for patients with atrioventricular (AV) block  Robert talked about the study design and the key findings from the study evaluating Medtronic’s Micra AV device  The interview gives an understanding…
December 6, 2022

Read more

Viewpoints_Priya Singhal
VIEWPOINTS

Priya Singhal, Senior Vice President at Biogen, Shares Insights from Litifilimab Systemic Lupus Erythematosus NEJM Publication

Shots: Priya spoke about the study design and key findings from the P-II (LILAC), P-III (TOPAZ-1) & (TOPAZ-2) clinical study evaluating litifilimab She also talked about the P-III trial evaluating Dapirolizumab pegol in collaboration with UCB to treat SLE The interview summarizes how Biogen’s innovative medications are helping patients with Systemic Lupus Erythematosus which has…
November 30, 2022

Read more

Viewpoints_Patrick Mooney
VIEWPOINTS

Patrick Mooney, CEO at SpyGlass Pharma, Shares Insights from the 3-Month Data of its Innovative Drug Delivery Platform for Chronic Eye Conditions

Shots: Patrick spoke about the 3-month data from the First-in-Human glaucoma treatment trial of Spyglass’ innovative  drug delivery platform that helps in lowering intraocular pressure in patients with glaucoma or ocular hypertension Patrick also talked about the study design and key findings from the First-in-Human glaucoma treatment trial The interview gives an understanding of Spyglass’…
November 29, 2022

Read more

Viewpoints_Dr. Navdeep Tangri_Helen Yeh
VIEWPOINTS

Dr. Navdeep Tangri & Helen Yeh Shares Insights from the Data Presented at ASN Kidney Week 2022 on the Importance of Earlier Screening & Diagnosis of Chronic Kidney Disease

Shots: Dr. Navdeep spoke about the data presented at the ASN Kidney Week 2022 emphasizing on the urgent need for early screening of chronic kidney disease Helen Yeh talked about the treatment of CKD with Farxiga. She also focused on the patient support programs by AstraZeneca for the early diagnosis and screening of patients The…
November 21, 2022

Read more

Viewpoints_Dr. Susana Banerjee
VIEWPOINTS

Dr. Susana Banerjee, Medical Oncologist at The Royal Marsden Shares Insights from the SOLO-1 P-III Trial of Lynparza in Patients with BRCA Mutated Ovarian Cancer

Shots: Dr. Susan talked about the results from the SOLO-1 P-III trial of Lynparza in patients with BRCA mutated (BRCAm) newly diagnosed advanced ovarian cancer presented at ESMO’22 Dr. Susan also spoke about the overall survival of this 7-year follow-up study.The 7-year follow-up of SOLO-1 showed that olaparib provided a clinically meaningful improvement in OS…
November 14, 2022

Read more

Viewpoints_Dr. Bill La Via
VIEWPOINTS

Dr. Bill La Via, Medical Director at Sanofi Shares Insights from the Findings that Support the Need of Protecting Infants from Respiratory Syncytial Virus (RSV)

Shots: Bill spoke about Respiratory Syncytial Virus and how it can severely affect infants' health Bill also talked about the 14 studies on RSV published in the Journal of Infectious Diseases (JID) The interview gives an understanding of how Sanofi’s vision to develop innovative solutions to help reduce the burden of RSV on infants, families,…
November 9, 2022

Read more

Viewpoints_Simon Portsmouth
VIEWPOINTS

Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacterial Infections

Shots: Simon spoke about the new data on FETROJA (cefiderocol), an antibiotic for the treatment of serious Gram-negative (highly resistant) bacterial infections He also talked about Shionogi’s agreement with GARDP & CHAI for the manufacturing and commercialization of cefiderocol in different countries The interview summarizes how Shionogi is advancing by developing medicines to treat serious…
November 7, 2022

Read more

Load more